<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654860</url>
  </required_header>
  <id_info>
    <org_study_id>PAR.3/02-2015</org_study_id>
    <nct_id>NCT02654860</nct_id>
  </id_info>
  <brief_title>Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia</brief_title>
  <official_title>Two-part Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia in Patients Scheduled for Hip Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sintetica SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sintetica SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-part study of intrathecal paracetamol administered immediately before spinal anaesthesia&#xD;
      in patients scheduled for hip replacement surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single centre, two-part, three doses study. Part 1 is a Phase I, three&#xD;
      cohorts, dose-ascending, open-label, safety study. Part 2 is a Phase II, randomised,&#xD;
      parallel-group, double-blind, placebo-controlled, exploratory efficacy and safety study The&#xD;
      objective of the study is to investigate the efficacy and safety of a single intrathecal&#xD;
      injection of paracetamol, administered at 3 doses to 3 active treatment groups, as compared&#xD;
      to placebo solution, for post-operative analgesia of hip replacement surgery performed under&#xD;
      spinal anaesthesia. Patients scheduled for hip replacement surgery will be randomised into 4&#xD;
      treatment groups (15 patients per group) to receive either one of the 3 single doses of&#xD;
      paracetamol 3% (D1: 60 mg, D2: 90 mg, D3: 120 mg) or placebo solution (P: saline solution) by&#xD;
      intrathecal (IT) injection. Immediately after paracetamol or placebo IT administration, all&#xD;
      patients will receive a single IT dose of Hyperbaric Bupivacaine HCl 0.5% (12.5 mg for ≤ 160&#xD;
      cm-tall patients and 15 mg for &gt; 160 cm-tall patients). The time interval between paracetamol&#xD;
      IT and bupivacaine IT administrations should not exceed 2 min.&#xD;
&#xD;
      The study will include a screening phase (Visit 1, Days -21/1), a treatment phase&#xD;
      (paracetamol IT administration, anaesthesia and surgical procedure: Visit 2, Day 1) and a&#xD;
      follow-up phase including an observation period (Visit 3, from Day 1 after surgery until&#xD;
      discharge, a final visit (at discharge) and a follow-up (day 6±1). Pain at rest will be&#xD;
      assessed at screening and on visit 2 at baseline (0 h), 1, 2, 3, 6, 9, 12, 15, 18, 21, 24,&#xD;
      27, 30, 33, 36, 39, 42, 45 and 48 h after anaesthetic IT injection and at discharge, using a&#xD;
      0-100 mm VAS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 arms for Phase II only</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Phase II only</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Number of Participants With Adverse Events Related, Not Related and Serious Events Related to Paracetamol</measure>
    <time_frame>In the first 24 hours, in the first 48 hours and at day 7±1</time_frame>
    <description>Phase 1: Number of participants with treatment evaluation and confirmation of the safety of the three doses of paracetamol 3% solution administered in the total number of patients enrolled</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Pain Intensity</measure>
    <time_frame>baseline (0 h), 1, 6, 9, 12, 15, 24, and 48 h after anaesthetic IT injection and at discharge</time_frame>
    <description>Phase 2: Pain intensity at rest evaluated as VAS scores ( 0-100 mm visual analogue scale : 0 is the absence pain and 100 is the maximum pain sensation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Morphine</measure>
    <time_frame>At 24 and 48 h after anaesthetic IT injection and entire study period, up to 7 days</time_frame>
    <description>Phase 2: Total morphine use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Time to First Morphine Use</measure>
    <time_frame>Postoperative, up to 48 hours after end of surgery</time_frame>
    <description>Phase 2: Time to first morphine use (minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Number of Participants With Need for Supplemental Analgesia</measure>
    <time_frame>Postoperative, up to 48 hours after end of surgery</time_frame>
    <description>Phase 2: Need for supplementary analgesia, other than the planned morphine PCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Morphine-related Adverse Events</measure>
    <time_frame>up to 24 hours after surgery, up to 48 hours</time_frame>
    <description>Percentage of subjects experiencing during the study the morphine-related adverse events pre-specified in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Time to Readiness for Surgery</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2:Maximum Level of Sensory Block</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Sensorial block will be verified by bilateral Pinprick test using a 20-G hypodermic needle and will be recorded. Pinprick sensation will be scored as being present (score 1) or absent (score 0). Onset of sensory block is defined as an absent touch sensation (score 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Time to Sensory Block</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Time to maximum level of sensory block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Time to Regression of Spinal Block</measure>
    <time_frame>from readiness for surgery,then every 10 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 30 min until regression of spinal block</time_frame>
    <description>Time period from spinal injection (time 0 h) to the time when the Bromage score returns to 0 and sensitive perception returns to S1. Bromage scale:&#xD;
I - Free movement of legs and feet II - Just able to flex knees with free movement of feet III - Unable to flex knees, but with free movement of feet IV - Unable to move legs or feet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Vital Signs</measure>
    <time_frame>at screening, at baseline (before the spinal injection) and at end of the study (Day 6).</time_frame>
    <description>Systolic and Diastolic Blood Pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2: Concomitant Medications</measure>
    <time_frame>at screening, at baseline until the end of the study (Day 6)</time_frame>
    <description>record the concomitant medications intaked during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: SpO2</measure>
    <time_frame>at screening, at baseline (before the spinal injection) and at the end of the study (day 6)</time_frame>
    <description>Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated + saturated) in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: ECG</measure>
    <time_frame>screening, baseline and end of study (Day 6±1)</time_frame>
    <description>Electrocardiography is the process of producing an electrocardiogram (ECG), it is a graph of voltage versus time of the electrical activity of the heart using electrodes placed on the skin.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Phase 1: Pain Management</condition>
  <condition>Phase 2: Pain Management</condition>
  <arm_group>
    <arm_group_label>60 mg Paracetamol 3% (2 mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg Paracetamol 3% (3 mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg Paracetamol 3% (4mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II Only: Saline solution 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 3%</intervention_name>
    <description>Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery</description>
    <arm_group_label>120 mg Paracetamol 3% (4mL)</arm_group_label>
    <arm_group_label>60 mg Paracetamol 3% (2 mL)</arm_group_label>
    <arm_group_label>90 mg Paracetamol 3% (3 mL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection containing Saline solution 0.9%</intervention_name>
    <description>Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.</description>
    <arm_group_label>Phase II Only: Saline solution 0.9%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperbaric Bupivacaine HCl 0.5%</intervention_name>
    <description>NIMP, spinal anaesthetic before the surgical procedure</description>
    <arm_group_label>120 mg Paracetamol 3% (4mL)</arm_group_label>
    <arm_group_label>60 mg Paracetamol 3% (2 mL)</arm_group_label>
    <arm_group_label>90 mg Paracetamol 3% (3 mL)</arm_group_label>
    <arm_group_label>Phase II Only: Saline solution 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Phase 1 and Phase 2:&#xD;
&#xD;
          -  Informed consent: signed written informed consent before inclusion in the study&#xD;
&#xD;
          -  Sex, age and surgery: male/female 18-80 years (inclusive) old patients, scheduled for&#xD;
             hip replacement surgery, with anticipated need for post-operative narcotic analgesia,&#xD;
             adequate i.v. access and anticipated hospital stay &gt; 48 hours.&#xD;
&#xD;
          -  Body Mass Index (BMI): 18 - 34 kg/m2 inclusive&#xD;
&#xD;
          -  ASA physical status: I-III&#xD;
&#xD;
          -  Full comprehension: ability to comprehend the full nature and purpose of the study,&#xD;
             including possible risks and side effects; ability to co-operate with the investigator&#xD;
             and to comply with the requirements of the entire study&#xD;
&#xD;
          -  Inclusion criteria - Phase 1 only : Age: 18-70 (inclusive) old patients&#xD;
&#xD;
          -  Inclusion criteria - Phase 2 only : Age: 18-80 (inclusive) old patients Hospital stay:&#xD;
             Patients with anticipated hospital stay &gt; 48 hours&#xD;
&#xD;
        Exclusion Criteria Phase 1 and Phase 2:&#xD;
&#xD;
          -  Physical findings: clinically significant abnormal physical findings which could&#xD;
             interfere with the objectives of the study. Contraindications to spinal anaesthesia.&#xD;
             History of neuromuscular diseases to the lower extremities&#xD;
&#xD;
          -  ASA physical status: IV-V&#xD;
&#xD;
          -  Further anaesthesia: patients expected to require further anaesthesia&#xD;
&#xD;
          -  Pain assessment: anticipated to be unable to make a reliable self-report of pain&#xD;
             intensity&#xD;
&#xD;
          -  Allergy: ascertained or presumptive hypersensitivity to the active principles&#xD;
             (paracetamol and/or amide type anaesthetics) and/or formulations' ingredients or&#xD;
             related drugs, opioids, non-steroidal anti-inflammatory drugs; history of anaphylaxis&#xD;
             to drugs or allergic reactions in general, which the investigator considers could&#xD;
             affect the outcome of the study&#xD;
&#xD;
          -  Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular,&#xD;
             respiratory, skin, haematological, endocrine or neurological diseases that may&#xD;
             interfere with the aim of the study; ascertained psychiatric and neurological&#xD;
             diseases, sepsis, blood coagulation disorders, severe cardiopulmonary disease, thyroid&#xD;
             disease, diabetes, other neuropathies, history or evidence of asthma or heart failure.&#xD;
             History of severe head trauma that required hospitalisation, intracranial surgery or&#xD;
             stroke within the previous 30 days, or any history of intracerebral arteriovenous&#xD;
             malformation, cerebral aneurism or CNS mass lesion.&#xD;
&#xD;
          -  Liver function: Impaired liver function (transaminases &gt; twice upper limit)&#xD;
&#xD;
          -  Renal function: Renal dysfunction (creatinine &gt; 2.0 mg/dL)&#xD;
&#xD;
          -  Investigative drug studies: participation in the evaluation of any investigational&#xD;
             product for 3 months before this study, calculated from the first day of the month&#xD;
             following the last visit of the previous study&#xD;
&#xD;
          -  Drug, alcohol: history of drug or alcohol abuse. Pre-existing dependence on narcotics&#xD;
             or known tolerance to opioids&#xD;
&#xD;
          -  Pregnancy and lactation: positive pregnancy test at screening (if applicable),&#xD;
             pregnant or lactating women [The pregnancy test will be performed to all fertile women&#xD;
             and to all women up to 55 years old, if not in proven menopause (available laboratory&#xD;
             test confirming menopause or surgically sterilised)]&#xD;
&#xD;
          -  Chronic pain syndromes: patients with chronic pain syndromes (taking opioids,&#xD;
             anticonvulsant agents or chronic analgesic therapy).&#xD;
&#xD;
          -  Medications: medication known to interfere with the extent of spinal blocks for 2&#xD;
             weeks before the start of the study. Paracetamol formulations, other than the&#xD;
             investigational product, for 1 week before the start of the study and during the&#xD;
             study. Hormonal contraceptives for females are allowed.&#xD;
&#xD;
          -  Phase 2 only - Exclusion criteria Pain assessment: anticipated to be unable to make a&#xD;
             reliable self-report of pain intensity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Camponovo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiology,Clinica Ars Medica,Via Cantonale, CH-6929 Gravesano, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Claudio Camponovo</name>
      <address>
        <city>Gravesano</city>
        <state>Lugano</state>
        <zip>CH-6929</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <results_first_submitted>May 5, 2021</results_first_submitted>
  <results_first_submitted_qc>May 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2021</results_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02654860/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>60 mg Paracetamol 3% (2 mL)</title>
          <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
        <group group_id="P2">
          <title>90 mg Paracetamol 3% (3 mL)</title>
          <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
        <group group_id="P3">
          <title>120 mg Paracetamol 3% (4mL)</title>
          <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
        <group group_id="P4">
          <title>Phase II Only: Saline Solution 0.9%</title>
          <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Part</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Part</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>60 mg Paracetamol 3% (2 mL)</title>
          <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
        <group group_id="B2">
          <title>90 mg Paracetamol 3% (3 mL)</title>
          <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
        <group group_id="B3">
          <title>120 mg Paracetamol 3% (4mL)</title>
          <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
        <group group_id="B4">
          <title>Phase II Only: Saline Solution 0.9%</title>
          <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.9" spread="6.7"/>
                    <measurement group_id="B2" value="65.1" spread="7.9"/>
                    <measurement group_id="B3" value="62.3" spread="9.3"/>
                    <measurement group_id="B4" value="65.1" spread="7.7"/>
                    <measurement group_id="B5" value="64.8" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase 1: Number of Participants With Adverse Events Related, Not Related and Serious Events Related to Paracetamol</title>
        <description>Phase 1: Number of participants with treatment evaluation and confirmation of the safety of the three doses of paracetamol 3% solution administered in the total number of patients enrolled</description>
        <time_frame>In the first 24 hours, in the first 48 hours and at day 7±1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Number of Participants With Adverse Events Related, Not Related and Serious Events Related to Paracetamol</title>
          <description>Phase 1: Number of participants with treatment evaluation and confirmation of the safety of the three doses of paracetamol 3% solution administered in the total number of patients enrolled</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse event related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event not related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 2: Pain Intensity</title>
        <description>Phase 2: Pain intensity at rest evaluated as VAS scores ( 0-100 mm visual analogue scale : 0 is the absence pain and 100 is the maximum pain sensation)</description>
        <time_frame>baseline (0 h), 1, 6, 9, 12, 15, 24, and 48 h after anaesthetic IT injection and at discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Pain Intensity</title>
          <description>Phase 2: Pain intensity at rest evaluated as VAS scores ( 0-100 mm visual analogue scale : 0 is the absence pain and 100 is the maximum pain sensation)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="15.5"/>
                    <measurement group_id="O2" value="17.3" spread="15.6"/>
                    <measurement group_id="O3" value="24.5" spread="19.5"/>
                    <measurement group_id="O4" value="10.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after anaesthetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours after anaesthetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="22.2"/>
                    <measurement group_id="O2" value="32.2" spread="25"/>
                    <measurement group_id="O3" value="20.3" spread="25.3"/>
                    <measurement group_id="O4" value="42.3" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 hours after anaesthetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="18"/>
                    <measurement group_id="O2" value="13.6" spread="11.6"/>
                    <measurement group_id="O3" value="17.3" spread="24"/>
                    <measurement group_id="O4" value="26.3" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours after anaesthetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="16.5"/>
                    <measurement group_id="O2" value="10.1" spread="8.6"/>
                    <measurement group_id="O3" value="11.2" spread="17.5"/>
                    <measurement group_id="O4" value="17.9" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 hours after anaesthetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="16.7"/>
                    <measurement group_id="O2" value="10.2" spread="10.2"/>
                    <measurement group_id="O3" value="10.6" spread="13.8"/>
                    <measurement group_id="O4" value="20.5" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after anaesthetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="10.7"/>
                    <measurement group_id="O2" value="9.5" spread="8.9"/>
                    <measurement group_id="O3" value="13.6" spread="14.9"/>
                    <measurement group_id="O4" value="16" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours after anaesthetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="8.6"/>
                    <measurement group_id="O2" value="3.2" spread="6.6"/>
                    <measurement group_id="O3" value="7.7" spread="12.9"/>
                    <measurement group_id="O4" value="8.7" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="3.7"/>
                    <measurement group_id="O2" value="4.1" spread="4.8"/>
                    <measurement group_id="O3" value="4.8" spread="6.8"/>
                    <measurement group_id="O4" value="8.0" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Morphine</title>
        <description>Phase 2: Total morphine use</description>
        <time_frame>At 24 and 48 h after anaesthetic IT injection and entire study period, up to 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Morphine</title>
          <description>Phase 2: Total morphine use</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>first 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="10.4"/>
                    <measurement group_id="O2" value="12.6" spread="4.5"/>
                    <measurement group_id="O3" value="22.8" spread="14.7"/>
                    <measurement group_id="O4" value="14.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>first 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="19.7"/>
                    <measurement group_id="O2" value="15.8" spread="5.1"/>
                    <measurement group_id="O3" value="33.5" spread="21.5"/>
                    <measurement group_id="O4" value="21" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>entire study period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="19.7"/>
                    <measurement group_id="O2" value="15.8" spread="5.1"/>
                    <measurement group_id="O3" value="33.8" spread="21.4"/>
                    <measurement group_id="O4" value="21.1" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Time to First Morphine Use</title>
        <description>Phase 2: Time to first morphine use (minutes)</description>
        <time_frame>Postoperative, up to 48 hours after end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Time to First Morphine Use</title>
          <description>Phase 2: Time to first morphine use (minutes)</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351" lower_limit="275" upper_limit="503"/>
                    <measurement group_id="O2" value="236" lower_limit="181" upper_limit="322"/>
                    <measurement group_id="O3" value="318" lower_limit="184" upper_limit="415"/>
                    <measurement group_id="O4" value="279" lower_limit="169" upper_limit="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Number of Participants With Need for Supplemental Analgesia</title>
        <description>Phase 2: Need for supplementary analgesia, other than the planned morphine PCA</description>
        <time_frame>Postoperative, up to 48 hours after end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Number of Participants With Need for Supplemental Analgesia</title>
          <description>Phase 2: Need for supplementary analgesia, other than the planned morphine PCA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Morphine-related Adverse Events</title>
        <description>Percentage of subjects experiencing during the study the morphine-related adverse events pre-specified in the protocol</description>
        <time_frame>up to 24 hours after surgery, up to 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Morphine-related Adverse Events</title>
          <description>Percentage of subjects experiencing during the study the morphine-related adverse events pre-specified in the protocol</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Time to Readiness for Surgery</title>
        <description>Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery.</description>
        <time_frame>Intraoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Time to Readiness for Surgery</title>
          <description>Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5" upper_limit="16"/>
                    <measurement group_id="O2" value="10" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O3" value="10" lower_limit="5" upper_limit="11"/>
                    <measurement group_id="O4" value="8" lower_limit="5" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2:Maximum Level of Sensory Block</title>
        <description>Sensorial block will be verified by bilateral Pinprick test using a 20-G hypodermic needle and will be recorded. Pinprick sensation will be scored as being present (score 1) or absent (score 0). Onset of sensory block is defined as an absent touch sensation (score 0)</description>
        <time_frame>Intraoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2:Maximum Level of Sensory Block</title>
          <description>Sensorial block will be verified by bilateral Pinprick test using a 20-G hypodermic needle and will be recorded. Pinprick sensation will be scored as being present (score 1) or absent (score 0). Onset of sensory block is defined as an absent touch sensation (score 0)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Time to Sensory Block</title>
        <description>Time to maximum level of sensory block</description>
        <time_frame>Intraoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Time to Sensory Block</title>
          <description>Time to maximum level of sensory block</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="13" upper_limit="20"/>
                    <measurement group_id="O2" value="15" lower_limit="9" upper_limit="20"/>
                    <measurement group_id="O3" value="15" lower_limit="13" upper_limit="20"/>
                    <measurement group_id="O4" value="17" lower_limit="10" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Time to Regression of Spinal Block</title>
        <description>Time period from spinal injection (time 0 h) to the time when the Bromage score returns to 0 and sensitive perception returns to S1. Bromage scale:&#xD;
I - Free movement of legs and feet II - Just able to flex knees with free movement of feet III - Unable to flex knees, but with free movement of feet IV - Unable to move legs or feet</description>
        <time_frame>from readiness for surgery,then every 10 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 30 min until regression of spinal block</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Time to Regression of Spinal Block</title>
          <description>Time period from spinal injection (time 0 h) to the time when the Bromage score returns to 0 and sensitive perception returns to S1. Bromage scale:&#xD;
I - Free movement of legs and feet II - Just able to flex knees with free movement of feet III - Unable to flex knees, but with free movement of feet IV - Unable to move legs or feet</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285" lower_limit="260" upper_limit="345"/>
                    <measurement group_id="O2" value="246" lower_limit="228" upper_limit="280"/>
                    <measurement group_id="O3" value="265" lower_limit="245" upper_limit="303"/>
                    <measurement group_id="O4" value="280" lower_limit="232" upper_limit="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: Vital Signs</title>
        <description>Systolic and Diastolic Blood Pressure (mmHg)</description>
        <time_frame>at screening, at baseline (before the spinal injection) and at end of the study (Day 6).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: Vital Signs</title>
          <description>Systolic and Diastolic Blood Pressure (mmHg)</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>systolic Blood Pressure at screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" spread="20.4"/>
                    <measurement group_id="O2" value="144.6" spread="20.5"/>
                    <measurement group_id="O3" value="148.5" spread="14.7"/>
                    <measurement group_id="O4" value="147.7" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>systolic Blood Pressure at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.5" spread="13.6"/>
                    <measurement group_id="O2" value="146.3" spread="19.2"/>
                    <measurement group_id="O3" value="138.7" spread="10.5"/>
                    <measurement group_id="O4" value="144.8" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>systolic Blood Pressure at end of the study (day6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="14.6"/>
                    <measurement group_id="O2" value="130.3" spread="11.3"/>
                    <measurement group_id="O3" value="133.5" spread="10.2"/>
                    <measurement group_id="O4" value="138.1" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure at screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" spread="11.3"/>
                    <measurement group_id="O2" value="85.7" spread="7"/>
                    <measurement group_id="O3" value="90.9" spread="8.2"/>
                    <measurement group_id="O4" value="87" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="8.8"/>
                    <measurement group_id="O2" value="78.9" spread="10.3"/>
                    <measurement group_id="O3" value="77.8" spread="10"/>
                    <measurement group_id="O4" value="85.9" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure at end of the study (day6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" spread="10.8"/>
                    <measurement group_id="O2" value="78.2" spread="7.5"/>
                    <measurement group_id="O3" value="79" spread="6.8"/>
                    <measurement group_id="O4" value="83.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase2: Concomitant Medications</title>
        <description>record the concomitant medications intaked during the study</description>
        <time_frame>at screening, at baseline until the end of the study (Day 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase2: Concomitant Medications</title>
          <description>record the concomitant medications intaked during the study</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>heparin group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second-generation cephalosporins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solutions affecting the electrolyte balance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct factor Xa inhibi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amino acids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>propofol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adrenergic and dopaminergic agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Propionic acid derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrazolones</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetic acid derivatives and related substances</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osmotically acting laxatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proton pump inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotonin (5HT3) antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benzodiazepine derivatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANTIEMETICS AND ANTINAUSEANTS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other opioids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet aggregation inhibitors excl. heparin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotensin II antagonists,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Natural opium alkaloids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: SpO2</title>
        <description>Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated + saturated) in the blood.</description>
        <time_frame>at screening, at baseline (before the spinal injection) and at the end of the study (day 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: SpO2</title>
          <description>Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated + saturated) in the blood.</description>
          <units>Oxygen Saturation percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.93" spread="0.59"/>
                    <measurement group_id="O2" value="98" spread="0.53"/>
                    <measurement group_id="O3" value="98.27" spread="0.70"/>
                    <measurement group_id="O4" value="97.80" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.27" spread="1.03"/>
                    <measurement group_id="O2" value="97.07" spread="1.03"/>
                    <measurement group_id="O3" value="97.33" spread="1.18"/>
                    <measurement group_id="O4" value="96.87" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>end of the study (day 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.73" spread="1.03"/>
                    <measurement group_id="O2" value="97.53" spread="0.83"/>
                    <measurement group_id="O3" value="97.8" spread="0.77"/>
                    <measurement group_id="O4" value="97.6" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2: ECG</title>
        <description>Electrocardiography is the process of producing an electrocardiogram (ECG), it is a graph of voltage versus time of the electrical activity of the heart using electrodes placed on the skin.</description>
        <time_frame>screening, baseline and end of study (Day 6±1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 mg Paracetamol 3% (2 mL)</title>
            <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O2">
            <title>90 mg Paracetamol 3% (3 mL)</title>
            <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O3">
            <title>120 mg Paracetamol 3% (4mL)</title>
            <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
          <group group_id="O4">
            <title>Phase II Only: Saline Solution 0.9%</title>
            <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2: ECG</title>
          <description>Electrocardiography is the process of producing an electrocardiogram (ECG), it is a graph of voltage versus time of the electrical activity of the heart using electrodes placed on the skin.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>screening</title>
              <category_list>
                <category>
                  <title>normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <title>normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>end of study</title>
              <category_list>
                <category>
                  <title>normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Clinical study duration (7 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>60 mg Paracetamol 3% (2 mL)</title>
          <description>60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
        <group group_id="E2">
          <title>90 mg Paracetamol 3% (3 mL)</title>
          <description>90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
        <group group_id="E3">
          <title>120 mg Paracetamol 3% (4mL)</title>
          <description>120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.&#xD;
Paracetamol 3%: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
        <group group_id="E4">
          <title>Phase II Only: Saline Solution 0.9%</title>
          <description>Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Placebo injection containing Saline solution 0.9%: Injection containing sterile solution of Saline Solution 0.9 %.&#xD;
Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.&#xD;
Hyperbaric Bupivacaine HCl 0.5%: NIMP, spinal anaesthetic before the surgical procedure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspespsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>epigastric disconfrort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>procedural nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>postprocedural constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>urinary retention postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>procedural vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>prupritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>antiementic supportive care</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Elisabetta Donati, Corporate Director Scientific Affairs</name_or_title>
      <organization>Sintetica SA</organization>
      <phone>+41.91.640.42.50</phone>
      <email>edonati@sintetica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

